Pfizer advancing precision oncology with Concerto HealthAI collaboration

Pfizer plans to integrate the real-world data and advance AI capabilities of Concerto HealthAI to advance precision oncology.

It will do this by using Concerto HealthAI’s eurekaHealth platform, AI models and Real World Clinical Electronic Medical Record (EMR) and healthcare claims.

Data from clinical practices participating in the American Society of Clinical Oncology’s CancerLinQ initiative and others throughout the US will be utilised for the collaboration and is one of the most comprehensive Real World Data (RWD) sets available.

The collaboration’s goal is to quicken the pace for actionable patient insights for Pfizer‘s investigational therapies and commercialized therapeutics used in the treatment of solid tumours and hematologic malignancies.

“Pfizer believes real-world data have tremendous potential to inform how we develop and use medicines to improve patient outcomes,” said Chris Boshoff, Chief Development Officer, Oncology, Pfizer Global Product Development.

Jeff Elton, CEO of Concerto HealthAI, added: “We are using our definitive real-world data, AI-enabled abstraction, data science expertise, and strength in outcomes research to identify new and more precise treatment options; refine study designs; and speed up the completion times for various outcomes studies.”

The collaboration will conduct novel synthetic control arm and prospective RWD outcomes study designs for therapeutics that are both pre- and post-approval.

This builds on work in study designs based on RWD that CancerLinQ, Concerto HealthAI, and others have undertaken in collaboration with the U.S. Food and Drug Administration.

A Concerto HealthAI-Pfizer joint steering committee will oversee the collaboration. The first outcomes research and publications are expected in early 2020.


Mallinckrodt & Silence Therapeutics to develop RNAi therapeutics

Mallinckrodt & Silence Therapeutics to develop RNAi therapeutics

Mallinckrodt will work with Silence Therapeutics under a new collaboration to develop and commercialise novel RNA2 interference (RNAi) therapeutics for complement-mediated diseases. The agreement will...
New CRISPR license framework to encourage innovation

New CRISPR license framework to encourage innovation

MilliporeSigma and the Broad Institute of MIT and Harvard will together offer non-exclusive licenses to CRISPR IP under their respective control for use in...
AUM licenses first-in-class targeted cancer therapy

AUM licenses first-in-class targeted cancer therapy

Singapore’s AUM Biosciences (AUM) is licensing Inflection Biosciences first-in-class PIM/PI3K/mTOR inhibitors. Under the agreement, AUM will develop, manufacture and commercialise the inhibitors. Known as the IBL-300...

Related Articles


Please enter your comment!
Please enter your name here